EE311 Cost-Utility Analysis of Transcatheter Valve Replacement Using Valves With RESILIA Tissue for the Treatment of Aortic Stenosis in South Korea

Transcatheter aortic valve replacement (TAVR) is increasingly popular for treating aortic stenosis in South Korea. The latest TAVR valves use RESILIA, a bovine pericardial tissue treated with integrity-preservation technology. This involves chemically blocking residual free aldehyde groups to prevent calcium binding and glycerolisation to replace water with glycerol, protecting against structural valve deterioration (SVD) and enhancing durability. RESILIA is incorporated into the newest balloon-expandable valves on the SAPIEN platform. Although this new tissue increases valve costs, a recent study shows it offers a survival benefit compared to previous valve generations (HR=0.79, 95% CI 0.67, 0.93). The study aims to evaluate the cost-utility of the SAPIEN 3 Ultra RESILIA (S3UR) valve versus earlier SAPIEN valves (S3 and S3U) for treating aortic stenosis in South Korea.